Eli Lilly’s newly approved oral obesity treatment, Foundayo (orforglipron), is projected by Wall Street analysts to generate multibillion-dollar sales as early as 2026, though estimates vary considerably as investors weigh strong patient demand against the unpredictability of an early-stage commercial launch.
Brokerage forecasts for 2026 sales span a wide range. At the lower end, Guggenheim Partners anticipates about $1.5 billion. Several firms are more bullish: Bernstein places Foundayo in a $2 billion to $2.5 billion band for its first full year, while Citi’s forecast sits near $2.8 billion for 2026 and includes a view that peak annual sales could surpass $40 billion.
The divergent projections reflect two competing themes in analysts’ models - clear upside from strong demand for oral options and scalability advantages that could favor Lilly, and meaningful uncertainty tied to the dynamics of an initial market rollout.
Some strategists point to structural advantages in Foundayo’s profile that could help it gain share. UBS noted that, together with Novo Nordisk’s oral version of Wegovy, the two drugs could generate about $5 billion in 2026, suggesting the emergence of a substantial new oral class. J.P. Morgan highlighted operational attributes - easier manufacturing and fewer dosing restrictions - that support Foundayo’s position as a formidable challenger to Novo, and projected growth to roughly $6 billion by 2027.
At the same time, analysts caution that early revenue may be muted by launch mechanics. Bernstein analysts flagged several near-term headwinds that could temper initial dollar sales even as prescription volumes rise: the use of free samples, manufacturers and providers starting patients on lower initial doses, and pricing adjustments could all reduce early-period revenue. They added that weekly new-patient starts will be an important metric for markets to monitor as a barometer of demand trajectory.
Beyond launch considerations, the market landscape still gives a leg up to Novo’s oral Wegovy because of first-mover advantage and brand recognition that can attract early adopters. Analysts generally expect that the arrival of multiple oral therapies will expand the reach of obesity treatments over time.
Industrywide projections cited by analysts suggest a large market opportunity: Morningstar estimates that obesity medications could represent about one-third of a projected $180 billion global market by 2034.
Separately, some retail-focused investment tools and strategies reference these developments when assessing Eli Lilly as an equity. One such tool described in research materials evaluates LLY alongside many companies each month using more than 100 financial metrics to identify stocks with attractive risk-reward profiles. That tool highlighted past notable winners in its track record, citing examples such as Super Micro Computer and AppLovin, and offered investors a way to see whether LLY appears in its current strategies.
As the market digests Foundayo’s approval and early launch data, the trade-off between scaling an oral product rapidly and managing near-term revenue impacts from sampling, dosing practices and pricing will be central to how quickly Lilly narrows Novo’s early lead in the oral segment.